Aminopeptidase N (APN, EC 3.4.11.2), a 150 kDa glycoprotein with zinc-dependent metalloprotease activity ([@BIB34]), has a wide distribution and numerous physiological functions. Thus, in hematopoietic and epithelial cells, the enzyme is believed to be involved in the control of growth and differentiation ([@BIB39]). Moreover, APN was recently shown to be a target for inhibiting angiogenesis ([@BIB45]). In the intestinal brush-border membranes it participates in the final steps of digestion by cleaving peptides into their constituent amino acids. APN is also found in reproductive organs ([@BIB19]), and is very abundant in the kidney where it appears to cleave peptides, thereby preventing their reentry into the vasculature ([@BIB24]). At the renal brush-border membrane level, APN has been suggested to act as anion exchanger. The peptidase has also been reported to serve as a receptor for transmissible gastroenteritis virus ([@BIB15]), and simultaneously, [@BIB62] have reported that human APN is a target for coronavirus 229E, which plays a critical role in upper respiratory tract infection. Finally, APN has been shown to be identical to antigen p146 of type II alveolar epithelial cells of rat lung ([@BIB20]) and to human lymphocyte surface cluster differentiation antigen CD13 ([@BIB33]).

In the brain, peptidases play a key role in the metabolism of neuropeptides released from nerve endings, either in achieving their maturation from larger precursors or in carrying out their inactivation ([@BIB48]). APN, which preferably removes NH~2~-terminal neutral amino acids from peptide substrates, is a potential candidate to modulate signal transduction by hydrolyzing bioactive peptides such as the enkephalins in the CNS (review in [@BIB47]). One way to elucidate the functional role of APN activity is to study its regional distribution and to determine tissues where a co-localization with neuropeptide substrates occurs. A current approach to localize aminopeptidases is to use synthetic substrates, which give products easily detectable after hydrolysis by fluorimetry or high-performance liquid chromatography ([@BIB1], [@BIB22]). The limit of this methodology is the lack of sensitivity and resolution avoiding the discrete distribution of a given enzyme to be carried out. In the case of APN some studies on its localization have been done by using immunohistochemistry ([@BIB24], [@BIB55]). However, this procedure was not able to visualize APN in neuronal brain structures and the peptidase was reported to be essentially present in microvessels. Radioactive inhibitors which are usually small molecules have the advantage over antibodies to label the active site of the enzyme, quantitatively, in all tissues and species (review in [@BIB63]). In contrast, antibodies are generated from a given animal, and although the primary sequences of zinc metallopeptidases were shown to be highly conserved, a lack of antibody recognition could occur due to various glycosylation levels in different tissues and/or species or due to differences in the tertiary structure and epitope presentation of the enzyme in various tissues, as already shown in the case of angiotensin converting enzyme ([@BIB56]). Therefore, the binding of a competitive and specific radioiodinated inhibitor of APN offered a quick, simple and reproducible method for visualization and quantitation of the peptidase in its intact membrane-anchored form, even in regions where the enzyme is in a very low concentration ([@BIB63]).

Determination of the APN distribution in the brain was essential to evaluate the physiological relevance of this enzyme in peptide metabolism. The possible lack of selectivity due to the *in vitro* low specificity of such a widely distributed peptidase seems to be counterbalanced *in vivo* by the co-localization of the substrate and both its metabolizing enzyme(s) and receptor(s). Moreover, the involvement of APN in the physiological inactivation of neuropeptides could be confirmed by the use of specific antagonists capable of reversing the pharmacological responses induced either by administration of the endogenous effector or by an APN inhibitor. In this way, the role of APN, with the concomitant action of another metallopeptidase, neutral endopeptidase (NEP), has been firmly established ([@BIB8], [@BIB59]). Due to the complementary role of NEP and APN, selective inhibition of only one of these peptidases does not increase the endogenous enkephalin concentration to a sufficient level, leading to weak antinociceptive effects, whereas strong antinociceptive responses can be obtained after complete inhibition of both enzymes ([@BIB8], [@BIB10], [@BIB17], [@BIB41]). With the aim of visualizing APN in the CNS, a highly potent and selective APN inhibitor has been designed and then radioiodinated ([@BIB11], [@BIB12]). This radioligand, \[^125^I\]RB 129 (2(*S*)-benzyl-3-\[hydroxy(1′(*R*)-aminoethyl)phosphinyl\]propanoyl-[L]{.smallcaps}-3-iodo-tyrosine), appears to be appropriate for autoradiography, as its affinity is in the nanomolar range (*K* ~d~=3.4±0.3 nM in rat brain homogenates) and it is specific for APN ([@BIB11], [@BIB43]). Moreover, \[^125^I\]RB 129 was found to interact with a single class of binding sites in rat brain homogenates, and the specific binding was high, being almost 95% at the *K* ~d~ value ([@BIB43]). In this paper, the localization of APN, in brain and spinal cord, was done for the first time by visualization of \[^125^I\]RB 129 binding, with intestine tissue used as control.

Experimental procedures {#SEC1}
=======================

Animals
-------

Male Wistar rats, 200--220 g (Charles River, France) were used. Care of the animals was in accordance with standard ethical guidelines and under the control of Ethical Committee of the Faculty. Only the number of rats necessary to produce reliable scientific data were used (*n*=5).

Autoradiography
---------------

Animals were deeply anaesthetized with pentobarbital and perfused intracardially with 100 ml of saline (0.9% NaCl). After rat decapitation, the brain, spinal cord and intestine were rapidly removed and frozen in isopentane at −45°C, and stored at −80°C until use. Sections (20 μm thick) were cut on a Bright cryostat at −17°C, thaw-mounted onto Superfrost Plus slides, and stored at −20°C. All sections were warmed to room temperature just prior to incubation with ligands. The slides were incubated with 0.5 nM \[^125^I\]RB 129 in 50 mM Tris--HCl (pH 7.4)--5 mM MgCl~2~--0.2% bovine serum albumin for 120 min at room temperature. For non-specific binding, the slices were incubated as above but in the presence of 1 μM of unlabeled RB 129. At the end of the incubation, the slices were washed four times in ice-cold buffer (50 mM Tris--HCl (pH 7.4)--0.2% bovine serum albumin) for 5 min, followed by a rapid rinse in ice-cold water and then dried under a cold airstream. Then, the films were exposed for 2 days at room temperature and developed.

Materials
---------

The synthesis of RB 129 and of its ^125^I-radioiodinated analogue was performed as previously described ([@BIB11], [@BIB12]). The Superfrost Plus slides were purchased from Menzel-Gläser, and β-max films from Amersham (France).

Analysis of binding sites by densitometry
-----------------------------------------

PhosphoImager screens were laid on the top of the slide to begin the exposure. Five hours later, the images on the screen were acquired by Molecular Dynamics scanners and analyzed using ImageQuant software, converting into arbitrary values the relative optical densities.

Results
=======

Radioautograms were obtained in a series of coronal and sagittal sections of rat brain, spinal cord and intestine. In each case, the high levels of specific binding observed in the different tissue sections are reflected by well-defined total binding in each section while non-specific labeling remained very weak and homogenous ([Fig. 1](#FIG1){ref-type="fig"} ).Fig. 1Specific binding of the radiolabeled APN inhibitor \[^125^I\]RB 129. Radioautography of coronal sections at the level of the striatum in rat brain with 0.5 nM \[^125^I\]RB 129. (A) Total binding of \[^125^I\]RB 129. (B) \[^125^I\]RB 129 binding in the presence of 1 μM RB 129 (non-specific binding). Scale bar ∼5 mm.

In the brain, \[^125^I\]RB 129 labeling was very high in the meninges, choroid plexus ([Fig. 3F--H](#FIG3){ref-type="fig"}) and blood vessels, which appear as dark points on the slices ([Table 1](#TBL1){ref-type="table"} ).Table 1Distribution of APN in rat brainBrain structure\[^125^I\]RB 129 specific binding (arbitrary values)**Olfactory bulb**Glomerular layer380±15**Telencephalon**Anterior olfactory nucleus Anterior olfactory nucleus, dorsal208±10 Anterior olfactory nucleus, lateral215±20 Anterior olfactory nucleus, medial211±19 Anterior olfactory nucleus, ventral187±17 Anterior olfactory nucleus, posterior230±5Cortex Cingulate cortex330±8 Frontal cortex233±7 Parietal cortex, area 1240±14 Agranular insular cortex255±18 Lateral orbital cortex245±12 Infralimbic cortex270±22Caudate--putamen166±4Nucleus accumbens Anterior230±6 Posterior207±6Globus pallidus110±3Hippocampus112±6Lateral septal nucleus150±2Bed nucleus stria terminal235±21**Diencephalon**Thalamus Paraventricular thalamic nucleus, anterior238±3Zona incerta165±8Subthalamic nucleus208±7Medial preoptic nucleus245±25Hypothalamus PVN380±14 Dorsomedial nucleus189±10 Ventromedial nucleus171±19**Mesencephalon**Substantia nigra203±10Mamillary nucleus260±8Inferior colliculus305±18Superior colliculus269±12Periaqueductal gray matter Darkschewitsch nucleus215±3 Edinger--Westphal nucleus210±5Red nucleus140±8Interpeduncular nucleus207±7Raphe nucleus267±11Pontine nucleus280±10**Metencephalon**Cerebellum Granular layer298±16 Molecular layer167±10 Interposed cerebellar nuclei261±22Tegmental nuclei295±10Cochlear nuclei274±18Inferior olive275±21Trigeminal nucleus170±18Facial nuclei306±17**Choroid plexus**Dorsal third ventricle495±9Lateral ventricle471±25**Spinal cord**Spinal gray matter Dorsal horn310±6 Ventral horn315±5**Meninges**Brain525±23Spinal cord523±22**Pituitary gland**Anterior pituitary492±38Posterior pituitary423±25**Pineal gland**1517±98

Olfactory bulb
--------------

In the glomerular layer of the olfactory bulb the labeling of APN was also very dense ([Table 1](#TBL1){ref-type="table"}, [Fig. 3A](#FIG3){ref-type="fig"}).

Telencephalon
-------------

A strong labeling was observed in the different parts of the anterior olfactory nucleus ([Table 1](#TBL1){ref-type="table"}; [Fig. 2](#FIG2){ref-type="fig"}, [Fig. 3](#FIG3){ref-type="fig"} ). High levels of binding were also found in the cortex (cingulate cortex, frontal cortex, parietal cortex, agranular insular cortex, lateral orbital cortex and infralimbic cortex) ([Fig. 3B--G](#FIG3){ref-type="fig"}). This was also the case for the anterior part of the nucleus accumbens ([Fig. 3C](#FIG3){ref-type="fig"}). Contrastingly, moderate to low labeling was found in the caudate--putamen, posterior part of the nucleus accumbens, globus pallidus, hippocampus, lateral septal nucleus and bed nucleus stria terminal ([Fig. 2](#FIG2){ref-type="fig"}, [Fig. 3](#FIG3){ref-type="fig"}).Fig. 2Distribution of APN in the rat brain labeled with the selective inhibitor \[^125^I\]RB 129. Radioautography of sagittal section showing the distribution of 0.5 nM \[^125^I\]RB 129 total binding in the rat brain. Labeling is particularly dense at the level of the meninges. Olfactory tubercle (Tu), pontine nucleus (Pn), inferior colliculus (IC) contain a moderate level of binding. The slides were incubated for 120 min at room temperature as described in [Experimental procedures](#SEC1){ref-type="sec"}. For non-specific binding, the slices were incubated in the presence of 1 μM of unlabeled RB 129. Scale bar ∼5 mm.Fig. 3Distribution of APN in the rat brain labeled with the selective inhibitor \[^125^I\]RB 129. Radioautography of coronal sections showing the distribution of 0.5 nM \[^125^I\]RB 129 total binding at different levels of the rat brain. (A) Olfactory bulb. (B) Frontal (Fr) and cingulate cortex (Cg), anterior olfactory nucleus (AO). (C,D) Cortex, caudate--putamen (CP), nucleus accumbens (Ac). (E) Cortex, caudate--putamen, lateral septal nucleus (LS), bed nucleus stria terminal (BST). (F) Cortex, striatum, globus pallidus (GP), bed nucleus stria terminal, paraventricular thalamic nucleus (PVA), medial preoptic nucleus (MPo), choroid plexus (ChP). (G) Hippocampus (Hi), paraventricular hypothalamic nucleus (PVN). (H) Zona incerta (ZI), subthalamic nucleus (STh). (I) Zona incerta, substantia nigra (SN), mamillary nucleus (Mn). (J) Periaqueductal gray matter level (PAG). (K) Superior colliculus (SC), periaqueductal gray matter, red nucleus (R), interpeduncular nucleus (IP), pituitary gland (Pit). (L) Pineal gland (Pi), interpeduncular nucleus, pituitary gland. (M) Inferior colliculus (IC), raphe nucleus (Ra), pontine nucleus (Pn). (N) Cerebellum, tegmental nuclei (Tg), olivary region (Ol). (O) Interposed cerebellar nuclei (Int), cochlear nuclei (Co), trigeminal nuclei (Tri), facial nucleus (Fa). The slides were incubated for 120 min at room temperature as described in [Experimental procedures](#SEC1){ref-type="sec"}. For non-specific binding, the slices were incubated in the presence of 1 μM of unlabeled RB 129. Scale bar ∼3 mm.

Diencephalon
------------

In the thalamus, the different nuclei exhibited moderate labeling ([Table 1](#TBL1){ref-type="table"}; [Fig. 2](#FIG2){ref-type="fig"}, [Fig. 3](#FIG3){ref-type="fig"}), as the medial preoptic nucleus ([Fig. 3F](#FIG3){ref-type="fig"}) and zona incerta ([Fig. 3H,I](#FIG3){ref-type="fig"}). The labeling was moderate in the ventromedial and dorsomedial nuclei of the hypothalamus ([Table 1](#TBL1){ref-type="table"}), but higher in the paraventricular nucleus (PVN) ([Fig. 3G](#FIG3){ref-type="fig"}).

Mesencephalon
-------------

Moderate binding was found in the substantia nigra ([Fig. 3I](#FIG3){ref-type="fig"}), interpeduncular nucleus ([Fig. 3K,L](#FIG3){ref-type="fig"}), raphe nucleus ([Fig. 3M](#FIG3){ref-type="fig"}) and pontine nuclei ([Fig. 2](#FIG2){ref-type="fig"}, [Fig. 3](#FIG3){ref-type="fig"}). In the periaqueductal gray matter the \[^125^I\]RB 129 labeling was also moderate, in the Darkschewitsch and Edinger--Westphal nuclei ([Fig. 3J,K](#FIG3){ref-type="fig"}). A high binding was observed in the inferior ([Fig. 3M](#FIG3){ref-type="fig"}) and superior colliculus ([Fig. 3K](#FIG3){ref-type="fig"}) and in the mamillary nucleus ([Fig. 3I](#FIG3){ref-type="fig"}), whereas the labeling was low in the red nucleus ([Fig. 3K](#FIG3){ref-type="fig"}).

Metencephalon
-------------

The labeling was moderate in the trigeminal nucleus, and high in the tegmental nuclei, cochlear nuclei, olivary region, and facial nuclei ([Table 1](#TBL1){ref-type="table"}; [Fig. 2](#FIG2){ref-type="fig"}, [Fig. 3](#FIG3){ref-type="fig"}). In the granular layer of the cerebellum and the anterior and posterior parts of interposed cerebellar nucleus ([Fig. 2](#FIG2){ref-type="fig"}, [Fig. 3](#FIG3){ref-type="fig"}) the \[^125^I\]RB 129 binding sites were present at relatively high levels, whereas the labeling was weaker in the molecular layer of the cerebellum.

The most intense labeling of \[^125^I\]RB 129 was observed in the pineal gland ([Table 1](#TBL1){ref-type="table"}; [Fig. 3L](#FIG3){ref-type="fig"}), and to a lesser extent in the anterior and posterior part of the pituitary gland ([Table 1](#TBL1){ref-type="table"}; [Fig. 3K,L](#FIG3){ref-type="fig"}).

In the spinal cord, a rather homogenous \[^125^I\]RB 129 labeling, restricted to the meninges and spinal gray matter (ventral and dorsal horn), was observed whatever the spinal level considered (cervical enlargement, thoracic level, lumbar enlargement, sacral level). A very poor binding was found scattered over the rest of the spinal cord ([Fig. 4](#FIG4){ref-type="fig"} ).Fig. 4Distribution of APN in the rat spinal cord labeled with the selective inhibitor \[^125^I\]RB 129. Radioautography of coronal sections showing the distribution of 0.5 nM \[^125^I\]RB 129 total binding in the cervical spinal cord. The binding sites are highly concentrated in the substantia gelatinosa. The slides were incubated for 120 min at room temperature as described in [Experimental procedures](#SEC1){ref-type="sec"}. For non-specific binding, the slices were incubated in the presence of 1 μM of unlabeled RB 129. Scale bar ∼12 mm.

In the intestine, the APN is visualized by \[^125^I\]RB 129 binding at the level of brush-border cells ([Fig. 5](#FIG5){ref-type="fig"} ).Fig. 5Distribution of APN in the rat intestine labeled with the selective inhibitor \[^125^I\]RB 129. Radioautography of rat intestine showing distribution of 0.5 nM \[^125^I\]RB 129 total binding in the intestinal membranes. The slides were incubated for 120 min at room temperature as described in [Experimental procedures](#SEC1){ref-type="sec"}. For non-specific binding, the slices were incubated in the presence of 1 μM of unlabeled RB 129. Scale bar ∼4 mm.

Discussion
==========

A detailed mapping of APN in the rat brain has been carried out for the first time using the highly selective radiolabeled APN inhibitor, \[^125^I\]RB 129 (*K* ~d~=3.4±0.3 nM in rat brain homogenates). The high selectivity of RB 129 for APN is supported by the non-specific labeling determined in the presence of an excess of unlabeled inhibitor which is almost undetectable in all regions studied, in good agreement with the results obtained in enzymatic and binding studies ([@BIB11], [@BIB43]).

In the brain, the pattern of labeling with this inhibitor shows clearly the presence of the peptidase on the brain microvessels, in agreement with previous studies using immunohistochemical detection ([@BIB24], [@BIB55]). Moreover, molecular and cellular studies have shown that APN is localized to the abluminal membrane of vessels, and more precisely at the level of astrocytic feet and pericytes which surround the microvessels ([@BIB4], [@BIB32]). A dense labeling was also observed at the level of meninges in brain and spinal cord, which form a barrier protecting both organs. The occurrence of an aminopeptidase-like activity in rat meninges was already reported ([@BIB64]) and confirmed by the specific APN labeling observed in the present study. Enzymatic activities at the levels of microvessels and meninges could represent a clearing system for regulatory peptides, and the presence of APN with other peptidases such as angiotensin converting enzyme and NEP ([@BIB64]) seems to support this hypothesis. Moreover, these enzymes could prevent the access of potentially harmful peptides to the brain or spinal cord. The aminopeptidase activity found in microvessels may also have physiological functions. Thus, it has been shown that APN rapidly hydrolyzes a number of vasoactive peptides at physiological pH ([@BIB44]), and may play a role in modulating their levels in the circulation and/or within the wall of the blood vessel. For instance, endogenous opioid peptides enkephalins are present in the human plasma ([@BIB46]) where they are probably degraded by both endothelial NEP ([@BIB54]) and APN (review in [@BIB47]). Moreover, in the microvessels APN may play an important role in immune functions, as opioid receptors are localized on immune cells (review in [@BIB7], [@BIB52]).

However, the most interesting result of this study is the autoradiographic data showing that APN is widely distributed throughout the CNS. In the brain, APN has been found to be involved in the degradation of neuropeptides, particularly the endogenous opioid peptides, enkephalins ([@BIB59]) in association with NEP, another zinc metallopeptidase (review in [@BIB47]). A moderate APN concentration was observed in the caudate--putamen where a dense labeling of NEP was shown to be present ([@BIB60]). Thus, the distribution of both enzymes and enkephalin peptides ([@BIB35]) occurred in this structure. This co-localization of APN, NEP and enkephalins is in agreement with the well-admitted interruption of the messages conveyed by these peptides ([@BIB14], review in [@BIB47], [@BIB59]). In addition to enkephalin fibers, the caudate--putamen of the rat contains scattered dynorphin-positive fibers, another opioid peptide degraded by APN ([@BIB49]), which may thus play a role in the regulatory mechanisms controlling the activity of this neuropeptide.

On the other hand, the pattern of \[^125^I\]RB 129 labeling clearly indicates the presence of APN in the central periaqueductal gray, several nuclei of the thalamus, and the dorsal horn of the spinal cord, where NEP and enkephalins are co-localized. These structures play a key role in control of nociceptive messages (reviews in [@BIB5], [@BIB6]) and it has been shown using dual NEP/APN inhibitors that enkephalins interact with opioid receptors in these areas to produce analgesia ([@BIB58]).

A dense labeling of the selective APN inhibitor was observed in the inferior colliculus which receives axons from most brainstem auditory nuclei. Unilateral lesions of the inferior colliculus produced sound localization deficits ([@BIB28]). The presence of APN in this region has not been associated until now with any functional effect. Nevertheless, NEP and enkephalins have previously been visualized in this brain area (review in [@BIB47]). Co-localization of these peptides and their metabolizing enzymes, NEP and APN, suggests that enkephalins could have several roles, in addition to nociception, such as the regulation of auditory functions. Thus, APN has been shown to be involved in the metabolism of a heptadecapeptide, nociceptin ([@BIB38], [@BIB42]), which is abundant in the inferior colliculus ([@BIB25]), where this peptide was reported to participate in the control of the auditory system. Accordingly, [@BIB40] have found defects in hearing recovery in mice lacking the nociceptin receptor and submitted to intense sound.

Integration of the hypothalamo--pituitary--adrenal (HPA) stress response occurs by means of interactions between stress-sensitive brain circuitry and neuroendocrine neurons of the hypothalamic PVN ([@BIB23]). The very high concentration of APN in both the pituitary gland and PVN suggests that this peptidase may have an important role in the HPA axis regulation. APN may regulate the endogenous enkephalins levels in these brain areas which exert a negative control on the HPA axis. Thus, it has been shown that blockade of opioidergic inhibitory input to corticotropin-releasing hormone-containing neurons of the PVN by the opioid antagonist, naloxone, induced an increase in plasma adrenocorticotropic hormone and cortisol ([@BIB61]). A functional deficiency of endogenous opioidergic inhibitory tone may be involved in depression, a disease marked by hyperactivity of the HPA axis (reviews in [@BIB3], [@BIB31]), or in the pathophysiology of drug addiction ([@BIB13], [@BIB21], [@BIB51]).

The highest concentration of APN labeled by \[^125^I\]RB 129 was found in the pineal gland. This structure contains multiple afferent peptidergic nerve fibers, with the presence of neuropeptide Y, norepinephrine, vasoactive intestinal peptide, substance P, calcitonin gene-related peptide, somatostatin or opioid peptides ([@BIB2]; review in [@BIB37]). APN may be involved in the regulation of different endogenous peptide levels which may directly modulate pineal function.

A large \[^125^I\]RB 129 binding was also observed in the cerebellum, where high amounts of NEP have also been visualized ([@BIB60]), while the distribution of both enkephalins and opioid receptors is sparce. The low concentration of the two opioid pentapeptides and their receptors contrasting with the relatively high levels of peptidases suggests that NEP and APN could be used to hydrolyze other still unknown peptide substrates in this structure.

APN is also visualized in other brain areas with a moderate to high labeling in the anterior olfactory nucleus, hippocampus, cortex, thalamus nuclei, nucleus accumbens and substantia nigra, suggesting that APN in these structures plays a role in the interruption of the enkephalinergic transmission involved in several functions such as locomotor activity, emotional responses, rewarding effects and memory processes ([@BIB47]). The rat substantia nigra contains the highest CNS concentration of immunoreactive substance P ([@BIB30]), and relatively high levels of Leu-enkephalin, supplied by striatonigral axons and generated from the precursor dynorphin ([@BIB65]). The physiological function of APN in this brain area has not been determined but the peptidase is probably involved in the regulation of enkephalin and dynorphin pathways.

As a control, distribution of APN has also been studied in the rat intestine. Binding of the radioiodinated inhibitor \[^125^I\]RB 129 was visualized in the brush border in agreement with previous studies using immunohistochemistry ([@BIB53], [@BIB57]). APN is anchored to the microvillar membrane via an uncleaved signal for membrane insertion. The physiological function of APN at this level could be to participate in the final steps of digestion, by cleaving peptides into their constituent amino acids. Moreover, the tonic participation of endogenous enkephalins at different levels of the gastrointestinal tract has been demonstrated using NEP inhibitor (reviews in [@BIB9], [@BIB47]). Thus, a naloxone-antagonized antidiarrheal effect of the NEP inhibitor thiorphan has been reported ([@BIB36]). It is due to the antisecretory action resulting from the stimulation of peripheral delta opioid receptors by the endogenous enkephalins tonically released from the submucosal plexus neurons ([@BIB29]). Given these results and because both NEP and APN are present in the gastrointestinal tract, it would be interesting to test the effects of orally administered mixed inhibitor ([@BIB47]).

In conclusion, using the highly potent and selective inhibitor \[^125^I\]RB 129, the presence of APN has been visualized for the first time in brain areas where it was suspected to be physiologically active. For instance, the present study demonstrates the co-localization of APN, NEP, enkephalins and opioid receptors in several regions, a result which was expected from numerous studies carried out with dual inhibitors, but not demonstrated until now. Nevertheless, APN, which preferably removes NH~2~-terminal neutral amino acids from peptides, has certainly other biologically active peptides as substrates. However, the possible physiological relevance of the degradation of these peptides, which remain to be characterized *in vivo*, is critically dependent on the extent of their tonic release. This might be investigated through appropriate behavioral experiments, provided that the receptor(s) of the peptide substrate should be characterized and the responses blocked by selective antagonists, as shown in the case of opioid system. Moreover, despite the relative broad specificities of APN, an *in vivo* selectivity is certainly achieved by the presence of the enzyme in brain areas where both the peptide and its receptors are co-localized.

On the other hand, the iodinated inhibitor could afford to study the localization of APN in various peripheral tissues, and to evaluate quantitatively its regulation in pathological situations ([@BIB26], [@BIB45]). Moreover, as previously demonstrated in the case of NEP ([@BIB16]) the distribution of APN could be monitored during pre- and post-natal development, to evaluate whether APN may have a modulatory role in the ontogeny of several organs. This radioiodinated compound could also be used to study the *in vivo* distribution of APN in various parts of the body after systemic administration, as already shown for NEP ([@BIB50]). Finally, the possibility to follow directly by competition the bioavailability of selective or dual NEP/APN inhibitors administered by different routes as already shown in the case of NEP and angiotensin converting enzyme ([@BIB18], [@BIB27]) is important considering the potential clinical application of these molecules (review in [@BIB47]).
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